SCHEMBL3676739

SCHEMBL3676739

O=C(On1c(=O)[nH]c2cc(-c3nc(-c4cccnc4)no3)ccc21)C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.49
CHRNB2 P17787 2/20 0.47
CHRNA5 P30532 2/20 0.47
CHRNA4 P43681 2/20 0.47
S1PR1 P21453 3/20 0.46
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
TP53 P04637 5/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
PKM P14618 1/20 0.46
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
ALDH1A1 P00352 2/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
LMNA P02545 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3676733 0.76 S1PR1 (0.54) MAPTCHRNB2CHRNA5CHRNA4S1PR1
SCHEMBL1422499 0.72 NPC1 (0.58) MAPTCHRNB2CHRNA5CHRNA4S1PR1
SCHEMBL1423161 0.72 CHRNB2 (0.61) MAPTCHRNB2CHRNA5CHRNA4S1PR1
SCHEMBL1422710 0.71 HDAC4 (0.66) MAPTCHRNB2CHRNA5CHRNA4S1PR1
SCHEMBL1423437 0.69 NPC1 (0.57) MAPTCHRNB2CHRNA5CHRNA4S1PR1
Trifluoroacetic Acid SCHEMBL1422776 0.68 NPC1 (0.64) MAPTCHRNB2CHRNA5CHRNA4S1PR1
SCHEMBL1423560 0.68 NPC1 (0.58) MAPTCHRNB2CHRNA5CHRNA4S1PR1
SCHEMBL1422804 0.68 CHRNB2 (0.61) MAPTCHRNB2CHRNA5CHRNA4S1PR1
SCHEMBL1423263 0.66 NPC1 (0.66) MAPTCHRNB2CHRNA5CHRNA4S1PR1
SCHEMBL1422372 0.66 KMO (0.67) MAPTCHRNB2CHRNA5CHRNA4S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040568-B2 Pharmaceutical compositions for the treatment of pain ABBVIE INC. (US) 2015-05-26 US disclosed
US-8486979-B2 Analgesics; central nervous system disorders; attentiondeficit disorders;cognition activators; bipolar disorders; Alzheimer's disease; Down's syndrome; brain disorders ABBVIE INC. (US) 2013-07-16 US disclosed
US-20100305086-A1 Pharmaceutical Compositions for the Treatment of Pain ABBOTT LABORATORIES (US) 2010-12-02 US disclosed
US-20080269236-A1 Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof ABBOTT LABORATORIES (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305086-A1 Pharmaceutical Compositions for the Treatment of Pain CHRNA1, CHRNG, CHRNA4 MAPT 1555/4885CHRNB2 14/4885CHRNA5 7/4885
US-20080269236-A1 Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof OXA1L, CYP11B2, CYP1B1 MAPT 2963/4885CHRNB2 3741/4885CHRNA5 4256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.